Related Experiment Video
Updated: Feb 27, 2026
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
New Dancing Couple: PD-L1 and MicroRNA
1Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.
Abstract:
Lung cancer (LC) is the most common cause of cancer death in the world. A great challenge in treating NSCLC is the discovery of advanced, molecular tools to diagnose the disease in early stages as well as the development of immunotherapy. MicroRNAs are regulatory molecules (~20 nt in length) with the ability to regulate the expression of genes. The recently described PD-1 and PD-L1 molecules have great importance for potential use in immunotherapy of many cancers. These molecules are associated with immune checkpoints and provide an opportunity for the treatment of advanced NSCLC patients with synthetic monoclonal antibodies. PD-L1 expression is strictly associated with microRNA function in lung cancer cells. The group of microRNAs related to PD-L1 includes, among others, miR-200, miR-197 or miRNA-34. Expression of these molecules may be useful in lung cancer diagnosis, qualification to anti-PD-1 or anti-PD-L1 antibody therapy and could be a potential therapeutic target. However, studies on PD-L1-related microRNAs are necessary to develop advanced targeted molecular therapies.
Insights
MicroRNAs regulate gene expression and are linked to PD-L1 in lung cancer. Studying these microRNAs could improve early diagnosis and immunotherapy for non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Lung cancer (LC) remains the leading cause of cancer mortality globally.
- Non-small cell lung cancer (NSCLC) treatment faces challenges in early diagnosis and effective immunotherapy development.
- MicroRNAs are small regulatory molecules influencing gene expression, with emerging roles in cancer.
Purpose of the Study:
- To explore the association between microRNAs and Programmed Death-Ligand 1 (PD-L1) in lung cancer.
- To investigate the potential of PD-L1-related microRNAs as diagnostic markers for early-stage NSCLC.
- To assess the utility of these microRNAs in patient selection for anti-PD-1/PD-L1 immunotherapy.
Main Methods:
- Review of current literature on microRNA function and PD-L1 expression in lung cancer.
- Analysis of specific microRNAs (e.g., miR-200, miR-197, miRNA-34) associated with PD-L1.
- Discussion of the implications for immunotherapy and targeted therapies in NSCLC.
Main Results:
- PD-L1 expression in lung cancer cells is significantly associated with microRNA function.
- Specific microRNAs, including miR-200, miR-197, and miRNA-34, are linked to PD-L1.
- These microRNAs show potential as biomarkers for NSCLC diagnosis and predicting response to immunotherapy.
Conclusions:
- PD-L1-related microRNAs represent a promising area for developing advanced molecular tools in lung cancer.
- Further research into these microRNAs is crucial for advancing targeted therapies and improving patient outcomes in NSCLC.
- MicroRNA expression profiling could aid in qualifying patients for immune checkpoint inhibitor therapy.
More Related Videos
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:57piRNA - Piwi-interacting RNAs
02:23Abnormal Proliferation